Company intelligence / Profile preview
Kiji Therapeutics
Paris, Île-de-France, Francekiji-tx.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Preclinical
01
Overview
Kiji’s lead products are iPSC-derived MSCs engineered with IL10 and CXCR4 to enhance immunomodulation and homing. Strong preclinical data support improved efficacy over traditional MSCs. The company has not yet reported clinical results but expects first-in-human studies in late–2025 for its GvHD program.
- Therapeutic areas
- GastroenterologyDermatologyImmunologyNeurology
- Modalities
- Induced pluripotent stem cell-derived mesenchymal stem cells (iPSC-MSCs)Gene-engineered cell therapiesMultigene engineering (e.g., IL10 and CXCR4 transduction)Small molecules and monoclonal antibodies via merger pipeline
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Collaborations with CIBERFundación Jiménez DíazCIEMAT academic institutions
Beyond the preview
Go deeper on Kiji Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kiji Therapeutics.